Struggling to confidently detect and quantify Mutagenic Impurities in APIs and Drug Products?

Mutagenic impurities in APIs and drug products pose a significant risk to health and safety—even in small quantities—and thus are a major concern for drug makers. Mutagenic impurities can damage DNA, leading to mutations and potentially cancer. Nitrosamines are formed by chemical reactions that occur during API manufacturing whether from starting materials, intermediates, reactants, reuse of solvents and by-products; they can form through degradation products generated during formulation or storage or from environmental contaminants. Regulatory agencies advise companies on steps to take to avoid nitrosamines in medicines.

Detection and quantification of these trace nitrosamines in APIs and drug products can be challenging and requires the use of advanced and sensitive tools to meet the required regulatory requirements. Agilent offers reliable systems and solutions that not only fulfill FDA directives, but also meet and exceed FDA’s established regulatory requirements to help pharmaceutical customers identify and quantify trace(ppb)nitrosamine and other mutagenic impurities confidently.

Be Agilent Sure for Nitrosamines: Not only the does Agilent experts help you technically but now also offers you Financial solutions to purchase high end technologies with easy payment plans.

With Agilent financial solutions we offer you:
• Customized Solution
• Flexible tenor
• Attractive financial offer
• Fixed and predictable cost
• After lease tenor – Easy – upgradation of asset

Download Nitrosamine Application Guide

    This is co-hosted by Express Pharma and Agilent

    By submitting this form, you are confirming you are an adult 18 years or older and agree to Express Pharma contacting you with marketing-related emails or by telephone. You may unsubscribe from receiving such communications from Express Pharma at any time. Express Pharma web sites and communications are subject to our Privacy Notice and Terms of Use.

    Yes, I would like to receive email updates about Agilent products, services and events.
    For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy

    Comments (0)
    Add Comment